| Progetti di ricerca attivi Nazionali con Finanziamento nel ruolo di PI |
| Bando |
Referente Scientifico (PI) |
Titolo del progetto |
Ente finanziatore |
Gestione |
|
CUNEO Antonio |
INTEGRATIVE "OMICS" APPROACHES FOR LEUKEMIA TARGET IDENTIFICATION AND MATCHED THERAPEUTIC INTERVENTION |
Azienda Ospedaliero-Universitaria di Parma |
OspFe |
| PRIN P2022A35RA_001 |
GIORGI Carlotta |
The molecular code of PTEN localization in tumor suppression |
Ministero dell'Università e della Ricerca |
UniFe |
|
GRECO Pantaleo |
Studio ID:7319 - Second stage of labor. Correlazione tra gli esiti materno-fetali e il tipo di assistenza del secondo stadio del travaglio di parto: uno studio osservazionale prospettico multicentrico |
Dipartimento Scienze Mediche, fondi di dipartimento; Università degli studi di Ferrara |
UniFe |
| Regione Emilia Romagna PNRR-MAD- 2022- 12376611 |
MANFREDINI Roberto |
EXercise ACTivity to improve mobility, active behavior and quality of life of chronic kidney disease patients with peripheral artery disease: the EXACTckd-pad multicenter randomized controlled trial |
Ministero Salute -Regione Emilia Romagna PNRR-MAD- 2022- 12376611 |
OspFe |
| PRIN 2022-PRIN-PP_001 |
PINTON Paolo |
"Biochemical mechanism and cellular consequences of mitochondrial cation flux: from bioenergetics to metabolic rewiring" |
Ministero dell'Università e della Ricerca |
UniFe |
| IIS |
RIGOLIN Gian Matteo |
CLL2222 (Gimema) - FRONT-LINE VENETOCLAX AND OBINUTUZUMAB COMBINATION FOLLOWED BY VENETOCLAX OR VENETOCLAX AND ZANUBRUTINIB COMBINATION IN PATIENTS WITH RESIDUAL DISEASE: A MINIMAL RESIDUAL DISEASE (MRD) TAILORED TREATMENT FOR YOUNG PATIENTS WITH HIGH-RISK CLL. A phase 2 multicenter study (VIS trial) |
centri GIMEMA (gruppo italiano malattie ematologiche) |
GINEMA |
| PNRR-MAD-2022-12376434 |
SUPPIEJ Agnese |
Alterations in GABA-A receptor subunit composition in temporal lobe epilepsy: pathogenetic role and foundation for a mechanistic, combinatorial gene therapy |
Ministero della Salute |
OspFe |
| Regione Emilia Romagna PNRR-MAD- 2022 |
VOLPATO Stefano |
Effect of infections and global DNA methylation on frailty trajectories in hospitalized older patients: a multicenter observational study |
Ministero della salute |
OspFe |
| PNRR-POC-2023-12378163 |
ZATELLI Maria Chiara |
MIRAGE: MIcroRnA-targeted imaging for monitorinG and prognostic stratification in nEuroendocrine tumors |
Ministero della Salute |
OspFe |
| PRIN-2022 |
BONORA Massimo |
hyPERTRAce - Tracing the genomic and biochemical regulations of cell fate by the mitochondrial PERmeability TRAnsition pore |
Ministero dell'Università e della Ricerca |
UniFe |
| Cariplo Telethon Alliance |
BONORA Massimo |
Functional characterization of the mitochondrial protein CCDC58 and its role in 3-methylglutaconic aciduria type 9 |
Telethon EST |
Telethon EST |
| IIS |
BORTOLUZZI Alessandra |
Effetti del farmaco Belimumab nelle donne con lupus eritematoso sistemico. Studio prospettico che monitora il biomarker coinvolto nella salute riproduttiva |
GSK |
UniFe |
| PRIN-2022 |
DE MATTEI Monica |
BIOCOAT - Novel Deposition Method for Biomedical Applications |
Ministero dell'università e della ricerca |
UniFe |
| PNRR |
FERLLINI Alessandra |
Progettazione, impostazione e validazione di uno studio di screening genetico neonatale multiregionale per più malattie rare per testare un approccio a livello nazionale utilizzando una doppia strategia digitale e genomica. |
Ministero Dell’Università e della Ricerca |
OspFe |
| AIRC |
GIULIANI Anna Lisa |
Repurposing purinergic signaling for cancer therapy |
AIRC (Italian Association for Cancer Research) |
UniFe |
|
JORI Alberto |
La dignità umana |
Accademia Nazionale Virgiliana |
|
| FIRD |
JORI Alberto |
Etica della cura in tempi di emergenza: per un nuovo “Giuramento di Ippocrate” |
Università di Ferrara |
UniFe |
| PRIN 2022, cod.P202242AFC_001 |
RIMESSI Alessandro |
Exploring mitochondrial-derived vesicles (MDVs) content, dynamics, and functions during inflammatory response |
Ministero dell'Università e della Ricerca |
UniFe |
| PRIN 2022 (MUR-Next GenerationEU) |
TREVISAN Caterina |
Metabolic dysregulation as biomarker of frailty: role of the mitochondrial dysfunction |
PRIN 2022 (MUR-Next GenerationEU) |
UniFe |
| AIRC |
PATERGNANI Simone |
Relevance of mitochondrial HMGB1 for malignant pleural mesothelioma: from the neoplastic transformation to the therapy |
AIRC (Italian Association for Cancer Research) |
UniFe |
| IIS |
SILVAGNI Ettore |
Identificazione di biomarcatori sinoviali di risposta a ixekizumab nei pazienti con artropatia psoriasica refrattaria: lo studio PRECISE |
Eli-Lilly |
OspFe |
| 2020/INFLA-THROMB MUR |
GIORGI Carlotta |
The inflammatory process beyond thrombotic events |
Ministero dell'Università e della Ricerca |
UniFe |
|
GRECO Pantaleo |
Studio ID:7360 - PROLAPSE_FE. Valutazione degli esiti anatomici e funzionali post trattamento chirurgico del prolasso uterovaginale: chirurgia fasciale e protesica a confronto |
Dipartimento Scienze Mediche, fondi di dipartimento; Università degli studi di Ferrara |
UniFe |
| PRIN 202259LHXM |
PINTON Paolo |
Exploring the role of ELOVL4 in squamous epithelia homeostasis and pathology: integrating lipid metabolism, ferroptosis and mitochondrial signaling cascades |
Ministero dell'Università e della Ricerca |
UniFe |
| IIS |
RIGOLIN Gian Matteo |
CLL2323 (Gimema) - Ibrutinib for the Treatment of Autoimmune Hemolytic Anemia in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or CLL-like monoclonal B-cell lymphocytosis |
centri GIMEMA (gruppo italiano malattie ematologiche) |
GINEMA |
| PRIN 2022 PNRR |
DE MATTEI Monica |
Bi-layers anti polymicrobial 3D printed patches loaded with yeast-derived exosome for wound healing (BIMODAL) |
Ministero dell'università e della ricerca |
UniFe |
| PNRR |
FERLINI Alessandra |
Testing novel nanodelivery of RNA molecules and synthetic genes as therapeutic approaches for muscular dystrophy |
Ministero dell'Università e della Ricerca |
UniFe |
| PRIN-PNRR |
GIULIANI Anna Lisa |
The extracellular ATP/P2X7 system for the efficient mRNA delivery via extracellular microvesicles |
Ministero dell'Università e della Ricerca |
UniFe |
| Fondazione Menarini |
JORI Alberto |
Body Perception and Self-Consciousness |
ASST Mantova Fondazione Menarini |
ASST Mantova |
| PRIN-2022-PNRR, cod.2022ALJN73 |
RIMESSI Alessandro |
Mitochondrial dysfunction associated to permeability transition pore phenomenon in lung inflammation controls mitochondria-derived vesicles biogenesis and release in cystic fibrosis |
Ministero dell'Università e della Ricerca |
UniFe |
| AISM |
PATERGNANI Simone |
Involvement of HMGB1 in Multiple sclerosis: role in ferritinophagy and AIM2 inflammasome activation |
Fondazione Italiana Sclerosi Multipla |
UniFe |
| PRIN 2022PX3S3R |
GIORGI Carlotta |
Unlocking the structure and function of the heme transporter FLVCR1 |
Ministero dell'Università e della Ricerca |
UniFe |
| PNRR-MCNT1-2023-12378355 |
GIORGI Carlotta |
Microbiota: its role in chronic inflamation, IBD and risk of colorectal cancer. Evaluation of predictive prognostic model with therapeutic implications |
Ministero della Salute |
UniFe |
|
GRECO Pantaleo |
Studio 6542 - HIE_AUTOPHAGY. Studio dei meccanismi di autofagia in relazione ai livelli plasmatici delle proteine ATG5- ATG7/Parkin-Optineurina e del danno placentare nella valutazione della encefalopatia ipossico- ischemica neonatale |
Dipartimento Scienze Mediche, fondi di dipartimento; Università degli studi di Ferrara |
UniFe |
| PRIN P2022WY85K_001 |
PINTON Paolo |
Mechanisms that modulate endoplasmic reticulum/mitochondria calcium signaling to improve cancer chemotherapy efficacy |
Ministero dell'Università e della Ricerca |
UniFe |
| IIS |
RIGOLIN Gian Matteo |
CLL1920 (Gimema) - An observational study to evaluate the clinical and biologic features and outcome of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) treated with venetoclax-based regimens outside clinical trials in Italy |
centri GIMEMA (gruppo italiano malattie ematologiche) |
GINEMA |
| TELETHON |
FERLINI Alessandra |
Characterization of the phenotypic diversity in DupEx2 Duchenne Muscular Dystrophy and identification of predictive/prognostic markers |
TELETHON |
UniFe |
| AIRC ID 23670 2024-AIRC-PP_001 |
PINTON Paolo |
Dissecting the role of Endoplasmic Reticulum-mitochondria calcium crosstalk in cancer |
AIRC (Italian Association for Cancer Research) |
UniFe |
| IIS |
RIGOLIN Gian Matteo |
AML1819 (Gimema) - Phase III study to assess the impact of gemtuzumab ozogamicin, in combination with standard chemotherapy, on the levels of minimal residual disease, in adult patients, aged 18-60 years, with previously untreated, de novo, favorable-intermediate-risk acute myeloid leukemia |
centri GIMEMA (gruppo italiano malattie ematologiche) |
GINEMA |
| TELETHON |
FERLINI Alessandra |
Natural history of Becker muscular dystrophy: toward trial readiness |
TELETHON |
UniFe |
| IIS |
RIGOLIN Gian Matteo |
ALL2922 (Gimema) - Combination of Ponatinib Plus Chemotherapy As Frontline Treatment For Patients With BCR/ABL1-Like Acute Lymphoblastic Leukemia (BCR/ABL1-Like ALL) - BALLik |
centri GIMEMA (gruppo italiano malattie ematologiche) |
GINEMA |
| IIS |
RIGOLIN Gian Matteo |
MASTER FRAMEWORK FOR RELAPSE OR REFRACTORY ACUTE MYELOID LEUKEMIA. A PROSPECTIVE OBSERVATIONAL STUDY OF TREATMENT OUTCOMES |
IRCCS Istituto Romagnolo per lo studio dei tumori "Dino Amadori" |
OspFe |
| IIS |
RIGOLIN Gian Matteo |
CLL2423 (Gimema) - Incidence of severe COVID-19 infection in patients with chronic lymphocytic leukemia or indolent B-cell non-Hodgkin lymphoma who received pre-exposure prophylaxis with Tixagevimab and Cilgavimab in Italy: an observational study by the GIMEMA Working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi |
Astra Zeneca |
OspFe |
| Progetti di ricerca Internazionali con finanziamento nel ruolo di PI |
| Bando |
Referente Scientifico (PI) |
Titolo del progetto |
Ente finanziatore |
Gestione |
|
CUNEO Antonio |
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia |
BeiGene |
OspFe |
| ERC |
GIORGI Carlotta |
Promyelocytic leukemia protein (PML) outside the tumor: a new player in the control of inflammation |
ERC (European Research Council) |
UniFe |
|
GRECO Pantaleo |
Studio ID:6920 - SENTINEL-ENDO-OSPFE. Fattori di rischio associati al fallimento del mapping del linfonodo sentinella in pazienti con diagnosi di tumore dell'endometrio in stadio iniziale: uno studio retrospettivo |
Dipartimento Scienze Mediche, fondi di dipartimento; Università degli studi di Ferrara |
UniFe |
|
CAVAZZINI Francesco |
A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia who have an Inadequate Response to or are Intolerant of Hydroxyurea. |
Merck Sharp & Dohme LLC |
OspFe |
| HORIZON 2020 |
FERLINI Alessandra |
SCREEN4CARE |
Commissione Europea |
UniFe |
|
GIULIANI Anna Lisa |
Extracellular ATP is a key factor in promoting Alzheimer's disease neuroinflammation. |
Cure Alzheimer's Fund |
UniFe |
|
|
Ethics in Pandemic Times |
Center for Pandemic Studies |
|
|
CUNEO Antonio |
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia |
Janssen Research & Development |
OspFe |
|
CAVAZZINI Francesco |
A Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients |
Constellation Pharmaceuticals, Inc. |
OspFe |
| HORIZON 2020 |
FERLINI Alessandra |
EURO-NMD ERN |
Commissione Europea |
OspFe |
|
CUNEO Antonio |
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor |
Geron Corporation |
OspFe |
|
CAVAZZINI Francesco |
Ruxolitinib Observational study in Myelofibrosis treated patients in Italy - ROMEI |
Novartis Pharma AG |
OspFe |
|
CUNEO Antonio |
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome |
Genmab |
OspFe |
|
CUNEO Antonio |
Post-Authorisation Registry of ELZONRIS (Tagraxofusp) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) |
Stemline Therapeutics, B.V |
OspFe |
|
CUNEO Antonio |
A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) |
Janssen Pharmaceutica NV; AbbVie Inc.; F. Hoffmann-La Roche Ltd |
OspFe |
|
CUNEO Antonio |
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322) |
Loxo Oncology, Inc. |
OspFe |
|
CUNEO Antonio |
A prospective, open-label, multicenter, randomized phase III trial to compare the efficay and safety of a combined regimen of Obinutuzumab and GDC-0199 (ABT-199) versus Obinutuzumab and Chlorambucil in previously untreated patients with CLL and coexisting medical conditions |
Fortrea CAPS Ltd. |
OspFe |
|
CUNEO Antonio |
A single-arm, multicenter, nilotinib treatment-free remission study in patients with BCR-ABL1 positive Chronic Myelogenous Leukemia in chronic phase who have achieved durable minimal residual disease (MRD) status on first line nilotinib treatment |
Novartis |
OspFe |
| Progetti di ricerca attivi Internazionali con Finanziamento nel ruolo di Collaboratore |
| Bando |
Referente Scientifico (PI) |
Titolo del progetto |
Ente finanziatore |
Gestione |
| HORIZON 2020 |
TREVISAN Caterina |
AFFIRMO (ATRIAL FIBRILLATION INTEGRATED APPROACH IN FRAIL, MULTIMORBID, AND POLYMEDICATED OLDER PEOPLE) |
Commissione Europea |
UniPd |
| EJP RD JTC 2021 |
SUPPIEJ Agnese |
SeeMyLife:Holistic mixed approaches to capture the real life of children with Rare Eye Diseases |
European Joint Program Rare Diseases Comunità europea |
|
|
GRECO Pantaleo |
International Ovarian Tumour Analysis (IOTA) Phase 5 |
KU Leuven |
|
| PRIN-PNRR |
GIULIANI Anna Lisa |
Fluid biomarkers of neurodegeneration |
Ministero dell'Università e della Ricerca |
|
|
GOVONI Marcello |
FILOSOPHY: Studio prospettico, non interventistico sull'efficacia, la sicurezza e gli esiti correlati alla salute in pazienti affetti da artrite reumatoide attiva da moderata a grave trattati con Filgotinib (fase IV) |
Alfa-Sigma |
OspFe |
|
GOVONI Marcello |
ASTER: Anifrolumab Study for Treatment Effectiveness in the Real World Multi-National, Observational, Post-Launch Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice (fase IV) |
Astra-Zeneca |
OspFe |
|
GOVONI Marcello |
LAVENDER: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus who are Refractory and/or Intolerant to Antimalarial Therapy - D346BC00001 (fase III) |
Astra-Zeneca |
OspFe |
|
GOVONI Marcello |
BE-EARLY: 219240 - A Phase 4, multicenter, prospective, open-label study describing the efficacy and safety of belimumab administered subcutaneously in adult participants with early systemic lupus erythematosus. |
GSK |
OspFe |
|
GOVONI Marcello |
CVAY736F12302:A randomized, double-blind, placebo-controlled multicenter phase 3 study to evaluate efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 2) (fase III) |
Novartis |
OspFe |
|
GOVONI Marcello |
DAISY: A Multicenter, Randomized, Parallel-group, Double-blind, Two-arm, Phase III Study to Evaluate the Safety and Efficacy of Anifrolumab Compared with Placebo in Male and Female Participants 18 to 70 Years of Age Inclusive with Systemic Sclerosis |
Astra-Zeneca |
OspFe |
|
GOVONI Marcello |
218224 BLISSc-ILD:Studio di fase 2/3, randomizzato, in doppio cieco, controllato con placebo, con trattamento a gruppi paralleli volto a valutare l'efficacia e la sicurezza di belimumab somministrato sottocute in pazienti adulti affetti da sclerosi sistemica i stadio |
GSK |
OspFe |
|
GOVONI Marcello |
ALLEGORY: STUDIO DI FASE III, RANDOMIZZATO, IN DOPPIO CIECO, CONTROLLATO CON PLACEBO, MULTICENTRICO VOLTO A VALUTARE L'EFFICACIA E LA SICUREZZA DI OBINUTUZUMAB IN PAZIENTI AFFETTI DA LUPUS ERITEMATOSO SISTEMICO |
Roche |
OspFe |
|
GOVONI Marcello |
CAIN457R12301: Studio randomizzato, a gruppi paralleli, in doppio cieco, controllato con placebo, multicentrico di fase 3, per valutare sicurezza ed efficacia di secukinumab 300mg per via sottocutanea versus placebo, in combinazione con terapia steroidea, in pazienti con arterite a cellule giganti |
Novartis |
OspFe |
| HORIZON 2020 |
FERLINI Alessandra |
Solving the unsolved Rare Diseases |
Commissione Europea |
UniFe |
| EU/EFPIA Innovative Medicines Initiative Joint Undertaking HARMONY grant n◦ 116026. |
RIGOLIN Gian Matteo |
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY (Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in hematologY) |
AbbVie |
OspFe |
|
CUNEO Antonio |
A Phase 3 Multi-Center, Randomized, Controlled Study to Assess the Safety and Efficacy of Bomedemstat (IMG-7289) versus Best Available Therapy (BAT) in Patients with Essential Thrombocythemia who are Resistant to or Intolerant of Hydroxyurea |
Merck Sharp & Dohme LLC |
OspFe |
